Enzychem files patent application for COVID-19 drug candidate

By The Science Advisory Board staff writers

April 10, 2020 -- Enzychem Lifesciences has filed a provisional patent application with the U.S. Patent and Trademark Office to cover treating COVID-19 with its compound EC-18.

EC-18 can resolve inflammation by allowing complete viral clearance while minimizing tissue damage, and it may be able to quickly neutralize SARS-CoV-2 by preventing cytokine storm or acute respiratory distress syndrome, according to the company.

Now the company is seeking appropriate partners to develop and commercialize EC-18 worldwide as a potential treatment for COVID-19.


Copyright © 2020 scienceboard.net
 


MemberID or email address:

Password:
Forgot your password?